A detailed history of Pathstone Holdings, LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Pathstone Holdings, LLC holds 71,324 shares of ALKS stock, worth $2.11 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
71,324
Previous 41,276 72.8%
Holding current value
$2.11 Million
Previous $994,000 100.8%
% of portfolio
0.01%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$23.01 - $28.55 $691,404 - $857,870
30,048 Added 72.8%
71,324 $2 Million
Q2 2024

Aug 14, 2024

SELL
$23.21 - $27.24 $596,636 - $700,231
-25,706 Reduced 38.38%
41,276 $994,000
Q1 2024

May 13, 2024

BUY
$26.4 - $32.56 $1.2 Million - $1.48 Million
45,339 Added 209.49%
66,982 $1.81 Million
Q4 2023

Feb 14, 2024

BUY
$23.37 - $28.68 $505,796 - $620,721
21,643 New
21,643 $600,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.87B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Pathstone Holdings, LLC Portfolio

Follow Pathstone Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Holdings, LLC with notifications on news.